A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Registration Number
- NCT02231671
- Lead Sponsor
- Alios Biopharma Inc.
- Brief Summary
The purpose of this study is to see how ALS-008176 is taken up, broken down, and removed from the body.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
- Body mass index 18.0 to 32.0 kg/m2 (inclusive) and a total body weight >50 kg
Exclusion Criteria
- Creatinine clearance as calculated by the Cockroft-Gault formula of less than 60 mL/min
- Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator or the sponsor medical monitor. Reticulocyte count, haemoglobin and platelet counts must not be less than the lower limit of normal for the subject.
- History of clinically significant cardiovascular, renal, hepatic, chronic respiratory, GI, haematological, neurological, endocrinological, immunological, musculoskeletal disease or any uncontrolled medical illness (eg active infection) or psychiatric disorder, as judged by the investigator or medical monitor.
- Clinically significant abnormal electrocardiogram (ECG) findings
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part 1: Absolute Bioavilability ALS-008112 Part 1 of this study is an absolute bioavailability study where the IV (intravenous) microtracer dose of ALS-008112 is administered 15-30 minutes after the oral dose to determine the bioavailability of the oral dose compared to the IV dose. The maximum microtracer IV dose administered in Part 1 of this study will not exceed a single dose of 100 μg \[14C\]-ALS-008112 containing NMT (not more than) 37.0 kBq (1000 nCi) 14C. Based upon previous clinical observations, it is anticipated that the single oral dose and IV microdose to be utilised in Part 1 will provide acceptable PK data and will be safe and well tolerated. Part 2: Mass Balance ALS-008176 Part 2 of this study is an absorption, metabolism and excretion study, for which a single 375 mg \[14C\]-ALS-008176 (containing NMT 6.85 MBq (megabecquerel) (185 μCi) 14C) dose has been selected for evaluation based upon data from prior studies. Based upon previous clinical observations, it is anticipated that the dose to be utilised in Part 2 will provide acceptable PK data, will be safe and well tolerated and is within the therapeutic range. Part 1: Absolute Bioavilability ALS-008176 Part 1 of this study is an absolute bioavailability study where the IV (intravenous) microtracer dose of ALS-008112 is administered 15-30 minutes after the oral dose to determine the bioavailability of the oral dose compared to the IV dose. The maximum microtracer IV dose administered in Part 1 of this study will not exceed a single dose of 100 μg \[14C\]-ALS-008112 containing NMT (not more than) 37.0 kBq (1000 nCi) 14C. Based upon previous clinical observations, it is anticipated that the single oral dose and IV microdose to be utilised in Part 1 will provide acceptable PK data and will be safe and well tolerated.
- Primary Outcome Measures
Name Time Method Absolute Bioavailability Days 1-8 Determination of the absolute bioavailability of ALS-008112
Mass Balance Days 1 - 14 Mass balance recovery of total radioactivity in urine, faeces, and urine and faeces combined: amount excreted (Ae) and Ae as a percentage of the administered dose (%Ae)
- Secondary Outcome Measures
Name Time Method Safety Days 1-14 Safety will be evaluated by recording adverse events, clinical laboratory results, vital signs, 12-lead ECGs, physical exams, etc.
To investigate the metabolic profile of [14C] - ALS-008176 Days 1-14 To investigate the metabolic profile of \[14C\] - ALS-008176 in plasma, urine and faeces following oral administration in healthy male subjects (Part 2 only)
Trial Locations
- Locations (1)
Quotient Clinical
🇬🇧Nottingham, United Kingdom